Suppr超能文献

儿童癌症幸存者甲状腺功能异常风险的管理:德尔菲研究。

Management of childhood cancer survivors at risk for thyroid function abnormalities: A Delphi study.

机构信息

Division of Pediatric Hematology/Oncology, Hasbro Children's Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island.

General Academic Pediatrics, Dartmouth-Hitchcock Medical Center, New Hampshire, Lebanon.

出版信息

Pediatr Blood Cancer. 2022 Dec;69(12):e29942. doi: 10.1002/pbc.29942. Epub 2022 Sep 7.

Abstract

BACKGROUND

Thyroid function abnormalities can occur after treatment for childhood cancer. Evidence for the management of thyroid dysfunction among asymptomatic childhood cancer survivors (CCS) is lacking. We used a Delphi consensus methodology to expand guidelines for screening asymptomatic CCS at risk for thyroid dysfunction and explore recommendations for the clinical management of abnormal results.

PROCEDURE

A Delphi panel of 40 expert physicians representing oncology, endocrinology, and primary care participated in three rounds of anonymous, iterative questionnaires formatted as clinical scenarios. Consensus is defined as ≥ 90% of panelists agree with recommendation and disagreement as < 70% agree.

RESULTS

Panelists reached consensus that CCS treated with radiation including neck, total body, whole brain, brain including the hypothalamic-pituitary axis (HPA), and therapeutic meta-iodobenzylguanidine (MIBG) should have annual, lifelong screening using serum thyroid-stimulating hormone (TSH) and free T4 starting within one year off-treatment (98%). Panelists disagreed on continuing to screen CCS for thyroid dysfunction after immunotherapy associated with acute thyroid injury (31%-50%). There was also disagreement on indications for brain (17%-43%) or thyroid (50%-65%) imaging, laboratory tests to assess the HPA (29%-75%), and TSH threshold to initiate treatment of subclinical hypothyroidism. Lack of evidence was the most frequent rationale panelists offered for not recommending additional testing or medications. Panelists' recommendations did not vary by geography, specialty, or survivorship clinical experience.

CONCLUSIONS

Consensus was reached on most recommendations for screening and management of cancer treatment-related thyroid dysfunction. Screening after completion of thyroid-toxic immunotherapy, indications for imaging, and treatment of subclinical hypothyroidism are areas of disagreement for further investigation.

摘要

背景

甲状腺功能异常可发生于儿童癌症治疗后。缺乏无症状儿童癌症幸存者(CCS)甲状腺功能障碍管理证据。我们使用德尔菲共识方法扩展了筛查无症状CCS 甲状腺功能障碍风险的指南,并探讨了异常结果的临床管理建议。

过程

一个由 40 名代表肿瘤学、内分泌学和初级保健的专家组成的德尔菲小组参与了三轮匿名、迭代的问卷,形式为临床情景。共识定义为≥90%的小组成员同意推荐意见,<70%的成员同意为分歧。

结果

小组成员就接受包括颈部、全身、全脑、脑包括下丘脑-垂体轴(HPA)和治疗性 meta-碘苄胍(MIBG)在内的辐射治疗的 CCS 应每年使用血清促甲状腺激素(TSH)和游离 T4 进行终生筛查达成共识,起始时间为治疗结束后一年内(98%)。小组成员不同意对免疫治疗相关的急性甲状腺损伤(31%-50%)后继续筛查 CCS 甲状腺功能障碍。对脑(17%-43%)或甲状腺(50%-65%)成像、评估 HPA 的实验室检查(29%-75%)以及启动亚临床甲状腺功能减退治疗的 TSH 阈值的指示也存在分歧。缺乏证据是小组成员提出不建议进行额外检查或药物治疗的最常见理由。小组成员的建议不受地理位置、专业或生存临床经验的影响。

结论

在筛查和管理癌症治疗相关甲状腺功能障碍方面达成了大多数建议的共识。完成甲状腺毒性免疫治疗后、成像指征和亚临床甲状腺功能减退的治疗仍存在分歧,需要进一步调查。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验